Assessment of transcriptional activity genes associated with the IL‐17 signaling pathway in skin fibroblasts under the influence of adalimumab. Issue 6 (23rd October 2019)

• Record Type: Journal Article
• Authors: Grabarek, Beniamin Oskar; Wcisło‐Dziadecka, Dominika; Bednarek, Kinga; Kruszniewska‐Rajs, Celina; Gola, Joanna
• Is Part Of: Dermatologic therapy. Volume 32:Issue 6(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-10-23
• Subjects: adalimumab -- IL‐17 pathways -- psoriasis; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.13112
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: It is believed that IL‐17 is involved in the signaling pathways of nuclear factor κB (NFκB) and mitogen‐activated kinases (MAPKs). Adalimumab, a full anti‐TNF‐α monoclonal antibody, was used for treatment of moderate to severe psoriasis. This study aimed to investigate the effect of adalimumab on changes in the expression of genes associated with IL‐17 signaling pathways in normal human dermal fibroblast (NHDF) culture. NHDFs treated with adalimumab at 2, 8, and 24 hr were compared with those of control. Microarray technique and PANTHER program were used to determine the expression of genes. The number of mRNA IDs differentiating the culture displayed on adalimumab in comparison with the control culture (−3.0 < FC > + 3.0) was as follows: H‐2—32 mRNA ID, H‐8—3 mRNA ID, H‐2 and H‐8—47 mRNA ID, H‐8 and H‐24—1 mRNA ID. Analysis by the PANTHER program indicated that adalimumab significantly affects the six signaling pathways and 19 biological processes associated with IL‐17. The strongest changes in the expression profile concerned pathway genes associated with the chemokine and cytokine signaling pathway, the gonadotropin‐releasing hormone receptor pathway, and the CCKR signaling map.